Abstract
When administered in high dosages, salicylate acts as a vitamin K-antagonist: it induces a decrease of the plasma concentration of the Gla-containing coagulation factors and an accumulation of microsomal substrates for vitamin K-dependent carboxylase in the liver and in the lung. In vitro the drugs inhibit the DTT-dependent reductases which mediate the reduction of vitamin K epoxide and vitamin K quinone. NADH-dependent reductase and vitamin K-dependent carboxylase are not inhibited.
| Original language | English |
|---|---|
| Pages (from-to) | 727-736 |
| Number of pages | 10 |
| Journal | Thrombosis Research |
| Volume | 42 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - 15 Jun 1986 |
Cite this
Roncaglioni, M. C., Ulrich, M. M. W., Muller, A. D., Soute, B. A. M., de Boer-van den Berg, M. A. G., & Vermeer, C. (1986). The vitamin k-antagonism of salicylate and warfarin. Thrombosis Research, 42(6), 727-736. https://doi.org/10.1016/0049-3848(86)90109-X